Clinical trials: Overall Response Rate
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Overall Response Rate
Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions
The purpose of this study is to explore the efficacy and safety ofof bevacizumab plus cisplatin compare with cisplatin in the treatment of malignant serous effusion in patients with advanced adenocarcinoma
- Trial name
- NCT07090525
- Testing
- Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2, cisplatin 40mg/m2 intracavity injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qingdao Central Hospital
Overall Response Rate, Oncology
Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)
Aim to observe the application of MR-Linac for precision radiotherapy of tumours, analyse its therapeutic effect, toxic and side effects,Characteristics of dosimetric parameters etc.
- Conditions
- Overall Response Rate, Oncology, Radiation Toxicity, Quality of Life
- Trial name
- NCT06531681
- Testing
- MR-Linac
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- The Second Affiliated Hospital of Hainan Medical University
Overall Response Rate
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients
- Trial name
- NCT06277024
- Testing
- Combination of Cardonizumab with Lenvatinib and SOX regimen
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
Objective Response Rate, Progression-free Survival
Real-world Study for Patients With Advanced Hepatobiliary Tumors
The investigators design a large sample size study in the real-world to explore whether targeted therapy and immunotherapy can improve the survival, quality of life and drug safety of patients with advanced hepatobiliary tumors…
- Conditions
- Objective Response Rate, Progression-free Survival, Overall Survival, Disease Control Rate
- Trial name
- NCT03892577
- Testing
- Precision oncology including targeted therapy and immunotherapy
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking Union Medical College Hospital
Recurrent Cervical Carcinoma, Radiotherapy
Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma
Patients with recurrent or metastatic uterine cervical squamous carcinoma have very poor prognosis. For eligible patients, radiotherapy remains the choice, which has the most effective impact on the survival periods.
- Conditions
- Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor, Nimotuzumab
- Trial name
- NCT04664244
- Testing
- Combination of nimotuzumab and radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Lei Li
Tumor Response Rate, Overall Survival
TILA-TACE in Treatment of Hepatocellular Carcinoma
To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate.
- Trial name
- NCT03910140
- Testing
- TILA-TACE treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR
Epigenetic Biomarker for Osteosarcoma
hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down…
- Conditions
- Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR, Progression-free Survival, PFS, Overall Survival, OS
- Trial name
- NCT03336554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Progress-free Survival, Overall Response Rate
Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE
Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China.
- Conditions
- Progress-free Survival, Overall Response Rate, Adverse Events
- Trial name
- HOPES (NCT01291667)
- Volunteers
- 330 people
- Sponsor
- Shanghai CP Guojian Pharmaceutical Co., Ltd.